Ion Exchange Q4 FY26: Revenue growth holds, but margins compress sharply

Ion Exchange (India) Limited ended FY26 with higher consolidated operating income but materially lower profitability. For FY26, consolidated operating income was INR 29,148 million, up 6.5 percent year on year. Operating EBITDA fell to INR 2,102 million from INR 2,939 million, taking EBITDA margin down to 7.21 percent from 10.74 percent. Consolidated PAT declined to INR 1,432 million, and PAT margin dropped to 4.91 percent.

The pressure was most visible in Q4. Consolidated Q4 FY26 operating income increased 3.4 percent year on year to INR 8,633 million, but EBITDA dropped to INR 199 million and margin fell to 2.31 percent. PAT for the quarter came in at INR 243 million versus INR 632 million last year.

A big part of the year’s narrative was that demand and project activity remained intact, but execution, input costs, and disruptions weighed on margins.

FY26 business mix stays anchored in engineering

Ion Exchange continues to operate as an integrated water and environment solutions platform with three core segments. In FY26 consolidated revenue mix terms, engineering contributed 58 percent, chemicals 29 percent, and consumer products 13 percent.

Engineering remains the primary growth and scale engine. The company highlighted steady enquiry levels and growth in order flow driven by medium-sized opportunities. It also reported a major milestone with the commissioning of the raw water treatment plant for its IOCL Panipat refinery contract, which it described as the largest water treatment package awarded in India.

Chemicals recorded sequential and year on year turnover improvement, but the company cited two near-term issues: input cost pressure and costs associated with the Roha facility. Exports in March 2026 were also impacted by logistics disruptions due to the West Asia crisis.

Consumer products continued to see volume growth, with the company stating it is investing in the segment to achieve a significantly higher revenue platform.

Consolidated financial snapshot

Segment performance: growth with lower segment profitability

On a consolidated segmental basis, Q4 engineering revenue was broadly flat year on year at INR 5,539 million versus INR 5,553 million. Chemicals grew from INR 2,228 million to INR 2,297 million, and consumer products rose from INR 779 million to INR 1,047 million.

However, segment EBIT for Q4 declined across engineering and chemicals. Engineering EBIT fell to INR 215 million from INR 412 million and chemicals EBIT fell to INR 334 million from INR 522 million. Consumer products EBIT remained negative at INR -46 million.

For the full year on a standalone segmental view, consumer products showed the strongest growth in revenues, rising to INR 3,794 million from INR 2,902 million. Engineering revenues increased modestly to INR 16,716 million and chemicals to INR 7,180 million.

The key takeaway is that the company is still growing across segments, but the cost structure and execution environment in FY26 reduced profitability.

Operations and strategic moves: capacity, certification, and technology tie-ups

While FY26 margins were under stress, the company outlined several actions and milestones that could influence medium-term competitiveness.

In chemicals, the company completed commissioning of manufacturing lines at Roha and received certification from Water Quality Association for resins manufactured at Roha, which it said will improve access to international markets. This is a measurable step because it ties capacity readiness with a globally recognized certification, even though the Roha cost base impacted near-term margins.

In engineering and technology, Ion Exchange entered into a technology transfer and manufacturing collaboration with MANN + HUMMEL to manufacture ultrafiltration membranes and to transfer Membrane Bio-Reactor solution technology in India. This points to deeper vertical integration in membrane-based treatment solutions, which matters in desalination, reuse, and advanced wastewater applications.

The company also highlighted how the West Asia crisis affected planned dispatches for high-value engineering contracts to GCC geographies, although it said customer clearances have now been received to proceed with execution.

International execution and order visibility

Ion Exchange reported a healthy engineering order position and pipeline as of 31 March 2026. Total order book was about INR 26,433 million, and the bid pipeline was about INR 95,090 million.

Group company updates were also material. The subsidiary in Oman is executing a 20-year DBOOT contract for OMR 73.46 million (approximately INR 17,300 million) won from Petroleum Development Oman in February 2026, and the company stated execution is proceeding on schedule.

It also entered a project joint venture with a local Malawi partner for execution of a water treatment package for US dollars 18.1 million awarded by Northern Region Water Board Malawi.

These updates signal that the company is actively pursuing multi-year overseas opportunities, but FY26 also showed that geopolitical and logistics disruptions can directly impact execution and export shipments.

What investors should track from here

Ion Exchange ends FY26 with clear demand visibility, a diversified business mix, and concrete operational milestones such as IOCL Panipat commissioning, Roha line commissioning, and WQA certification. At the same time, FY26 exposed a sharper sensitivity to costs, execution timing, and external disruptions.

The near-term focus is likely to remain on margin recovery through price pass-through in chemicals, normalization of dispatch and export logistics, and smoother execution of international projects. The company also expects to complete the Sri Lankan contract closure by the second quarter of FY 2026-27.

The overall theme from Q4 FY26 is not a demand slowdown, but a profitability reset. If the order book converts as planned and cost pressures moderate, investors will look for evidence that margins can move back toward historical levels while the company continues to scale in advanced membranes and international projects.